局限期小细胞肺癌放疗省略临床靶区的疗效与安全性:大规模多中心真实世界研究
本研究纳入946例局限期小细胞肺癌患者,比较省略临床靶区(Omit-CTV)与传统CTV勾画的疗效与毒性。倾向评分匹配后每组265例,中位随访33.2个月,两组无进展生存和总生存均无显著差异,但Omit-CTV组放射性肺炎和食管炎发生率更低;免疫治疗亚组中Omit-CTV显示出更优的生存信号。
要点
- Omit-CTV组与CTV组疗效相当,无进展生存和总生存均无显著差异。
- Omit-CTV组放射性肺炎和食管炎发生率显著低于CTV组。
- 免疫治疗亚组中Omit-CTV组无进展生存和总生存均显著优于CTV组。
核心结论
- 在局限期小细胞肺癌大规模队列中,省略CTV与相似疗效和更低治疗相关毒性相关。
- 接受免疫治疗的患者中省略CTV显示出有希望的生存信号,值得进一步前瞻性验证。
研究设计与样本
- 多中心真实世界研究,纳入2016年2月至2025年2月间946例局限期小细胞肺癌患者。
- 按放疗策略分为Omit-CTV组(n=403)和CTV组(n=543),倾向评分匹配后每组265例纳入最终分析。
- 主要终点为无进展生存和总生存,次要终点包括首次失败模式和治疗相关毒性。
主要发现
- 中位随访33.2个月,客观缓解率CTV组69.4% vs Omit-CTV组72.8%。
- 中位无进展生存CTV组11.6个月 vs Omit-CTV组11.8个月(HR 0.93,95%CI 0.76-1.14,P=0.500)。
- 中位总生存CTV组30.7个月 vs Omit-CTV组35.8个月(HR 0.85,95%CI 0.66-1.10,P=0.220)。
- 局部复发模式无统计学显著差异(P=0.561)。
- Omit-CTV组放射性肺炎(1-2级20.0% vs 27.2%;≥3级3.4% vs 8.3%;P=0.004)和食管炎(1-2级32.1% vs 39.2%;≥3级5.7% vs 9.1%;P=0.037)发生率更低。
临床怎么用
- 局限期小细胞肺癌放疗时可考虑省略CTV以降低放射性肺炎和食管炎风险而不牺牲疗效。
- 接受免疫治疗的患者省略CTV可能带来生存获益,但需前瞻性研究确认。
局限性
- 为真实世界研究,存在选择偏倚,虽经倾向评分匹配仍不能完全消除混杂。
- 免疫治疗亚组分析为探索性,样本量有限,结论需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Routine Clinical Target Volume (CTV) coverage in limited-stage small cell lung cancer (LS-SCLC) aims to address microscopic extension but often increases toxicity without necessarily translating to improved disease control. Our objective was to determine whether omitting the CTV could preserve efficacy while reducing toxicity compared with conventional delineation, with exploratory contemporary immunotherapy subgroup analysis. METHODS AND MATERIALS: This study enrolled 946 LS-SCLC patients between February 2016 and February 2025. According to radiotherapy strategy, patients were classified into an Omit-CTV (n = 403) group and a CTV group (n = 543). Subsequently, propensity score matching yielded 265 patients per group for the final analysis. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Secondary endpoints included first-failure patterns and treatment-related toxicity. RESULTS: With a median follow-up of 33.2 months, response rates were similar between groups (ORR: 69.4% with CTV vs. 72.8% with Omit-CTV). Median PFS was 11.6 months in the CTV group versus 11.8 months in the Omit-CTV group (HR, 0.93; 95% CI, 0.76-1.14; P = 0.500), while median OS was 30.7 months and 35.8 months, respectively (HR, 0.85; 95% CI, 0.66-1.10; P = 0.220). Furthermore, no statistically significant difference was observed in local recurrence patterns (P = 0.561). Omit-CTV was associated with lower rates of radiation pneumonitis (Grade 1-2: 20.0% vs. 27.2%; Grade ≥ 3: 3.4% vs. 8.3%; P = 0.004) and esophagitis (Grade 1-2: 32.1% vs. 39.2%; Grade ≥ 3: 5.7% vs. 9.1%; P = 0.037). Among patients receiving immunotherapy, median PFS was not reached in the Omit-CTV group and 15.2 months in the CTV group (HR, 0.48; 95% CI, 0.24-0.96; P = 0.033), and median OS was not reached and 26.9 months, respectively (HR, 0.31; 95% CI, 0.11-0.85; P = 0.018). CONCLUSIONS: In this large-scale LS-SCLC cohort, Omit-CTV was associated with similar efficacy and lower rates of treatment-related toxicity, with a promising survival signal in patients receiving immunotherapy, warranting further prospective validation.
引用
- Wang X, Yu X, Liu X, et al. Efficacy and safety of omitting the clinical target volume in limited-stage small cell lung cancer: a large-scale multicenter real-world study. Radiother Oncol. 2026. PMID: 42763051. doi:10.1016/j.radonc.2026.111784
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。